Equities research analysts forecast that Horizon Pharma PLC (NASDAQ:HZNP) will announce $304.01 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Horizon Pharma’s earnings. The lowest sales estimate is $301.90 million and the highest is $306.25 million. Horizon Pharma reported sales of $302.84 million in the same quarter last year, which would suggest a positive year over year growth rate of 0.4%. The business is expected to report its next earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Horizon Pharma will report full-year sales of $1.25 billion for the current financial year, with estimates ranging from $1.24 billion to $1.27 billion. For the next financial year, analysts forecast that the company will report sales of $1.40 billion, with estimates ranging from $1.36 billion to $1.44 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.20. The company had revenue of $280.00 million during the quarter, compared to analysts’ expectations of $238.35 million. Horizon Pharma had a negative net margin of 6.34% and a positive return on equity of 34.09%. Horizon Pharma’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same period last year, the business earned $0.03 EPS.
HZNP stock traded down $0.43 during trading on Friday, reaching $28.05. The company had a trading volume of 1,712,096 shares, compared to its average volume of 1,804,194. The stock has a market capitalization of $5.25 billion, a PE ratio of 15.33, a price-to-earnings-growth ratio of 1.51 and a beta of 1.09. The company has a quick ratio of 1.97, a current ratio of 2.03 and a debt-to-equity ratio of 1.80. Horizon Pharma has a twelve month low of $13.70 and a twelve month high of $29.44.
In other Horizon Pharma news, EVP Geoffrey M. Curtis sold 10,080 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $21.21, for a total transaction of $213,796.80. Following the completion of the transaction, the executive vice president now directly owns 35,367 shares of the company’s stock, valued at approximately $750,134.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.10% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Daiwa Securities Group Inc. purchased a new position in shares of Horizon Pharma during the 1st quarter valued at approximately $29,000. Private Capital Group LLC increased its holdings in shares of Horizon Pharma by 141.5% during the 4th quarter. Private Capital Group LLC now owns 1,963 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,150 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new position in shares of Horizon Pharma during the 1st quarter valued at approximately $38,000. Manchester Capital Management LLC purchased a new position in shares of Horizon Pharma during the 1st quarter valued at approximately $41,000. Finally, Quadrant Capital Group LLC purchased a new position in shares of Horizon Pharma during the 1st quarter valued at approximately $53,000. 82.38% of the stock is owned by institutional investors.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Story: What is an investor looking for in an SEC filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.